These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
761 related articles for article (PubMed ID: 32310915)
1. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]. Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915 [TBL] [Abstract][Full Text] [Related]
2. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Verdecchia P; Cavallini C; Spanevello A; Angeli F Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612 [TBL] [Abstract][Full Text] [Related]
3. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Albini A; Di Guardo G; Noonan DM; Lombardo M Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe? Shyh GI; Nawarskas JJ; Cheng-Lai A Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364 [TBL] [Abstract][Full Text] [Related]
5. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Danser AHJ; Epstein M; Batlle D Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987 [TBL] [Abstract][Full Text] [Related]
6. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166 [TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic. Dworakowska D; Grossman AB J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235 [TBL] [Abstract][Full Text] [Related]
8. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866 [TBL] [Abstract][Full Text] [Related]
9. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic. Vázquez-Cornejo E Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690 [TBL] [Abstract][Full Text] [Related]
10. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Kai H; Kai M Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442 [TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. Brojakowska A; Narula J; Shimony R; Bander J J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401 [TBL] [Abstract][Full Text] [Related]
12. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Rossi GP; Sanga V; Barton M Elife; 2020 Apr; 9():. PubMed ID: 32250244 [TBL] [Abstract][Full Text] [Related]
13. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study. Parit R; Jayavel S Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281 [TBL] [Abstract][Full Text] [Related]
14. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Steckelings UM; Sumners C Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019. Zheng H; Cao JJ Am J Pathol; 2020 Oct; 190(10):2013-2017. PubMed ID: 32735889 [TBL] [Abstract][Full Text] [Related]
16. Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Alexandre J; Cracowski JL; Richard V; Bouhanick B; Therapie; 2020; 75(4):319-325. PubMed ID: 32553503 [TBL] [Abstract][Full Text] [Related]
18. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Kreutz R; Algharably EAE; Azizi M; Dobrowolski P; Guzik T; Januszewicz A; Persu A; Prejbisz A; Riemer TG; Wang JG; Burnier M Cardiovasc Res; 2020 Aug; 116(10):1688-1699. PubMed ID: 32293003 [TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19. Hooper NM; Lambert DW; Turner AJ Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314 [TBL] [Abstract][Full Text] [Related]
20. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]